{"name":"MODAG GmbH","slug":"modag-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOOGhDYjBKcUZXZGY0SmRFLWlXYWdxWDJFa1NFY2hGZE5IcUxTSlNYZkJUenNNTGpjSnhqMHM1RmJmaTVNZVN5WjRzY2N6a1ZqRnZzN3F0QTBUdzdQMzVxVkNsSEg2V3pQYWJBTHBsTzVxdHNaaHpoaXdrVUw0Tm00SEtHeks3YXVDSUF1blZSV2t5bVBXTlYtelFyclIxcGU2WUFzTTFNN09kd1JKbkhYaVVUSVZuT292TnEtbTJ5Tm9Ta0NONDFoYkxLUlF0UUNDUEs1V25xVHFyRzVjSVhaMVJFeTMteEFBNGFPVnNBYUswNHYzc0tEVzV4akNsakZIRGVrTUx2Z0d0WGNLY1g3SW41SVc2ckg3djVTVmNRQUxZQ0NpSi14RTN1cDk2ZnRZY1FlZjBRSnh1ZUpOS0ptMF9VY2Z2VlcwYm84WmhpOA?oc=5","date":"2026-04-03","type":"pipeline","source":"Barchart.com","summary":"Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro -","headline":"Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxORlk1OUg3Tm8tbjQ1YTdpbERZQ242SUl2TUFiXzJwNHhWdl9fZ0FVanZpWXJSSUN1TEQtdzVfUjlTQnNqYVRyeWc1MjQxSU9oVUw4cmxVaTBlTDRjZVdfTG9MMVpnZFB3OWY0OUxsVFU1a1YyaTBza0o0VHU5OTkyYTk3YkFvU3B1OUV4c0ZNMXNaNFBuQTFUU1NkQ0FUODZMQXdLZERrY3RzT0sySkdYdWMtMUJwYTFNTU15VE9PXzFFZ3VabEFleXgxN0xkQ294U09YQ2RDeWpxNzVCcE4wTmJpNEtxYWN6eWJJNFVNM29Qa2hyQkNab3UtNmxVZw?oc=5","date":"2025-09-09","type":"regulatory","source":"GlobeNewswire","summary":"Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - GlobeNewswire","headline":"Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNcXJtbk85UXNjZTVHUUhFQlhzWHlOcjVZVENqWUc0c3hMbEs5TXEyeFh3Y0hkZC0teUNiNzBfUlFkbTVZd21LZHd3QmVJMjNPM05UVW0zaEo4SjFBTEdkV2V6cnpuRkYxS01kNzM5TFptSU1Va0JiZFI3cnFRWHBTWkkzUnVRN3paWi1UTW9keUtnaXd1S1NKZ2pyUEhYZ25aVEQzRVFFbW5JR2NjSTdQTWJZcnpoOGZGQ0VSRUR1Nlc0YTNqcVI3MzRfVFhKT1FEaWd0eUx5WXEybDVsM0JUcHIzNGVySnlsMGhPNHZxNFJJVDRlUjQ0REpwREw1Q0VnZjN1eVZKQjRldWFBRW5qdmJOV3Vqd2Mx?oc=5","date":"2025-07-28","type":"pipeline","source":"PR Newswire","summary":"Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight - PR Newswire","headline":"Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE0wb2hXMTBGcWt1SllNLVJpR3lVSFNMeG13U1VLWU80aXUzcjQ5cE94cXV4RXF3aWhsS3R3dERSTTAyUXdjTERZRUY3bThzbnRzMWZKbDN2WVJnejh6cEpDbTFrZGZETEE2NTZ0bXI2M2VlR2J6V2t3bG9hQ3U?oc=5","date":"2025-04-10","type":"pipeline","source":"Wiley","summary":"Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease - Wiley","headline":"Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1IemgzclhncHV1VVNDQW8wb2V6Z2d0VGN4aThmMUpscGxzVFZ1RDhkdnBuZzJJdUJtRERwazA1ZDZ3b1NJQmxTRkFMY2piSDU2enE1Q2VONDVXMWxFNm1tb3U0QWpuZUlmRjFuV0dIZmo0dTRhVkc0SEFxcURWUQ?oc=5","date":"2024-11-18","type":"pipeline","source":"Market.us Media","summary":"Top 10 Alzheimer’s Disease Therapeutics Companies | Provides Best Treatments - Market.us Media","headline":"Top 10 Alzheimer’s Disease Therapeutics Companies | Provides Best Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxObm10c2F4N2pxSEN5Qk9NN1ZKNjVzaDFsazI2RmVTTnRRWTZUSlhORkN4cDJnYzZHVkd5cWdfVWEzWGd4dlJmZ1lQclRnTG4yYmFzNUFobWM2Mm5FTGVNLXhnVE91YkN5ekhiYlMwUGFGQlpTT1ppWVE3Z2w4cUV0bTFydUdya1ZKU0xMUlhHWk1uQTNDS2NJaGlCUXFmQXBndW1Rd0E3NzdhY2FNQUFz?oc=5","date":"2021-10-28","type":"pipeline","source":"BioCentury","summary":"Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215M - BioCentury","headline":"Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPb2NtM1JZRU5QSFlCRGRCMGtaOHFKeV8zSHVURWRBOWJWUnA1bExrQ25JTFNyaWQxNlBJOXo4Q0N2YjRNN3BUNUdZdm1aS1dPU080anF1cUVUeGdEdDRCcVh6c0ZwWC1Pem1tQVVBS3BYYXpDbnFDa1N0TndQZ3pNbENCNEZGQXdFOGI2RTJJY1Mzb2R6OGhKR2tHN2lTRXBCMjNR?oc=5","date":"2021-10-27","type":"pipeline","source":"BioSpace","summary":"Teva and MODAG Tie Up on Potential Parkinson’s, MSA Treatment - BioSpace","headline":"Teva and MODAG Tie Up on Potential Parkinson’s, MSA Treatment","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}